Logo image of IMRX

IMMUNEERING CORP - CLASS A (IMRX) Stock Fundamental Analysis

NASDAQ:IMRX - Nasdaq - US45254E1073 - Common Stock - Currency: USD

1.76  +0.05 (+2.92%)

After market: 1.7896 +0.03 (+1.68%)

Fundamental Rating

2

IMRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While IMRX has a great health rating, there are worries on its profitability. IMRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMRX had negative earnings in the past year.
In the past year IMRX has reported a negative cash flow from operations.
IMRX had negative earnings in each of the past 5 years.
IMRX had a negative operating cash flow in each of the past 5 years.
IMRX Yearly Net Income VS EBIT VS OCF VS FCFIMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -72.74%, IMRX is doing worse than 66.61% of the companies in the same industry.
Looking at the Return On Equity, with a value of -84.56%, IMRX is in line with its industry, outperforming 50.44% of the companies in the same industry.
Industry RankSector Rank
ROA -72.74%
ROE -84.56%
ROIC N/A
ROA(3y)-37.84%
ROA(5y)-42.51%
ROE(3y)-42.16%
ROE(5y)-50.14%
ROIC(3y)N/A
ROIC(5y)N/A
IMRX Yearly ROA, ROE, ROICIMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

IMRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMRX Yearly Profit, Operating, Gross MarginsIMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

IMRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMRX has more shares outstanding than it did 1 year ago.
IMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMRX Yearly Shares OutstandingIMRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
IMRX Yearly Total Debt VS Total AssetsIMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

IMRX has an Altman-Z score of -2.14. This is a bad value and indicates that IMRX is not financially healthy and even has some risk of bankruptcy.
IMRX has a Altman-Z score (-2.14) which is in line with its industry peers.
There is no outstanding debt for IMRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.14
ROIC/WACCN/A
WACC9.44%
IMRX Yearly LT Debt VS Equity VS FCFIMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.39 indicates that IMRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.39, IMRX is in the better half of the industry, outperforming 78.33% of the companies in the same industry.
IMRX has a Quick Ratio of 9.39. This indicates that IMRX is financially healthy and has no problem in meeting its short term obligations.
IMRX has a Quick ratio of 9.39. This is in the better half of the industry: IMRX outperforms 78.69% of its industry peers.
Industry RankSector Rank
Current Ratio 9.39
Quick Ratio 9.39
IMRX Yearly Current Assets VS Current LiabilitesIMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

IMRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.35%.
The Revenue for IMRX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-5.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.95%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IMRX will show a small growth in Earnings Per Share. The EPS will grow by 5.71% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.44%
EPS Next 2Y6.72%
EPS Next 3Y-1.52%
EPS Next 5Y5.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMRX Yearly Revenue VS EstimatesIMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
IMRX Yearly EPS VS EstimatesIMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMRX Price Earnings VS Forward Price EarningsIMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMRX Per share dataIMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.72%
EPS Next 3Y-1.52%

More info and screens

0

5. Dividend

5.1 Amount

IMRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNEERING CORP - CLASS A

NASDAQ:IMRX (2/21/2025, 8:00:01 PM)

After market: 1.7896 +0.03 (+1.68%)

1.76

+0.05 (+2.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-05 2025-03-05/amc
Inst Owners13.99%
Inst Owner Change-93.13%
Ins Owners18.94%
Ins Owner Change0.11%
Market Cap54.65M
Analysts78.46
Price Target12.16 (590.91%)
Short Float %9.65%
Short Ratio0.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.41%
Min EPS beat(2)4.47%
Max EPS beat(2)12.35%
EPS beat(4)3
Avg EPS beat(4)5.59%
Min EPS beat(4)-9.09%
Max EPS beat(4)14.62%
EPS beat(8)7
Avg EPS beat(8)8.7%
EPS beat(12)9
Avg EPS beat(12)7.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.03%
PT rev (3m)6.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.38%
EPS NY rev (3m)-1.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-1.65
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0
BVpS2.14
TBVpS1.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.74%
ROE -84.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.84%
ROA(5y)-42.51%
ROE(3y)-42.16%
ROE(5y)-50.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.39
Quick Ratio 9.39
Altman-Z -2.14
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)160.54%
Cap/Depr(5y)166.33%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.95%
EPS Next Y-3.44%
EPS Next 2Y6.72%
EPS Next 3Y-1.52%
EPS Next 5Y5.71%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.54%
EBIT Next 3Y-15.21%
EBIT Next 5Y-19.96%
FCF growth 1Y-26.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.04%
OCF growth 3YN/A
OCF growth 5YN/A